The 3 Percent Buyback That Isn't About Conviction

Europap Tezol, a Turkish tissue and paper company that lost TRY 117 million in the first quarter of 2026, is buying back up to 3 percent of its own stock.

The program is capped at TRY 150 million and runs for one month - July 31 through August 31. The board resolution describes the purpose as protecting shareholders and supporting "healthy price formation." The official Turkish-language filing, posted to the country's public disclosure platform, also notes that the matter will be presented to shareholders at the next general assembly (Turkey's equivalent of an annual shareholder meeting) for ratification.

That last detail - the retroactive ratification - is where the story gets interesting.

This isn't a company signaling that its shares are deeply undervalued. This is a company taking advantage of a regulatory plumbing change that came online last year, and doing it on the most expedient schedule the rulebook allows.

The basic point is that Turkey's Capital Markets Board rewired how buybacks work back in March 2025. It issued decision 2025/16, which let listed companies start buyback programs by board resolution alone, without waiting for shareholder approval first. The regulator also suspended the old rule that a buyback couldn't exceed 10 percent of paid-in capital, removed the daily volume cap (which previously limited purchases to 25 percent of the prior 20-day average trading volume), and relaxed disclosure requirements.

Before the change, a company needed general assembly approval or a formal exemption from the regulator. Now the company just votes internally, announces it publicly, and tells shareholders about it at the next meeting. The program is valid for whatever duration the board specifies. TEZOL chose one month.

The economic intuition is straightforward: the barrier to running a buyback dropped from a formal shareholder vote to a board meeting and a public filing. Small, short, tactical buyback programs have become frictionless. A company can test the waters, put a bid into the market, and get shareholder approval later.

TEZOL's numbers help you see what sort of machine this is. The company has 500 million shares outstanding and a market capitalization of roughly TRY 4.85 billion. The maximum buyback of TRY 150 million - or 15 million shares - represents about 3 percent of outstanding equity and about 3 percent of market cap. That's on the order of a polite gesture.

And the gesture comes from a company whose stock has halved from its 52-week high of TRY 20.26 to the current range near TRY 9.60 to TRY 10.00. The stock trades at roughly 39 times trailing earnings - a premium that only holds up because the full 12-month window includes profitable quarters from earlier in 2025. The most recent quarter was a net loss of TRY 117 million, worse than the TRY 84 million loss in the same quarter of 2025.

This looks more like a program that exists because the rules now allow it than one that exists because management has reached a conviction about intrinsic value and wants to act on it with urgency. The one-month window reinforces that read. Companies buying back stock on conviction tend to give themselves longer to execute and larger budgets to work with. A month is barely enough time to figure out what you think the fair price is.

The other odd detail is the capital structure math. The company is authorized to spend TRY 150 million to buy shares. Its enterprise value is about TRY 3.6 billion, which implies roughly TRY 1.25 billion of net cash. The buyback budget is about 12 percent of that net cash position. The company is sitting on a substantial cash pile and is using a portion of it to retire equity.

In a textbook capital allocation framework, a company with net cash might consider returning cash to shareholders, but the small size and short duration of this buyback suggest it is not a conviction-driven decision. The buyback isn't trying to improve earnings per share; it's trying to improve the closing price.

The wider context matters too. The Turkish stock market has been volatile. The BIST 100 faced political-driven turbulence in May when a court annulled the main opposition party's congressional group, triggering sharp sell-offs. The market has been oscillating between inflows from local investors seeking inflation hedging and sudden risk-off spikes.

"Healthy price formation" - the phrase TEZOL uses in its filing - is respectable regulatory language for "we think the stock might be selling off for reasons that aren't really about the business." It's not wrong, necessarily. In a market environment where political headlines move indices by single digits, individual stocks do get caught in the crossfire. A small, targeted buyback can function as a circuit breaker for panic selling.

But it's worth separating two things: whether the buyback provides some marginal bid support on a wobbly day, and whether it represents a substantive statement about valuation. This program does the former. It is too small, too short, and too undercapitalized to credibly do the latter.

The final piece of the plumbing is what happens to the shares after the company buys them. Under the 2025/16 rules, repurchased shares cannot be sold for 30 days. After that, they can be disposed of within three years or retained indefinitely. So TEZOL could end up with treasury shares sitting on its balance sheet, creating the option to reissue them later for employee compensation, M&A currency, or whatever the company decides. That turns the buyback into something closer to a revolving equity facility than a permanent reduction in shares outstanding.

The simplest model is this: the regulator lowered the barrier to running a buyback, a company with a soft stock and a small war chest runs a one-month program to put a bid under the price, and shareholders ratify it later. Nobody is doing anything fraudulent. Nobody is hiding anything. But the program tells you more about how the Turkish regulatory machine has shifted than it does about the fundamental value of tissue paper in Turkey.

If you're watching TEZOL, the question isn't whether the buyback is a bullish signal. The question is whether earnings power is going to recover from the loss trajectory. The buyback is a rounding error relative to that. What matters is whether revenue can expand margins and whether debt reduction gets prioritized once the market stops wobbling. The TRY 150 million buyback is a drop of liquidity in a much larger balance sheet conversation.

This program will probably look exactly like dozens of others that Turkish listed companies have run since March 2025. They all share the same anatomy: a board resolution, a short window, a retroactive shareholder ask, and a respectable line about protecting investors. The common thread isn't conviction. It's regulation.